NCT03210220 is a NA clinical trial of Pecs II block in Breast Cancer, sponsored by Gachon University Gil Medical Center.

Who is sponsoring NCT03210220?

NCT03210220 is sponsored by Gachon University Gil Medical Center.

What drugs are being tested in NCT03210220?

Interventions in NCT03210220: Pecs II block.

What condition does NCT03210220 study?

NCT03210220 studies Breast Cancer.

Is NCT03210220 still recruiting?

NCT03210220 is currently completed. Last updated 18 November 2019.

Are results published for NCT03210220?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-11-18 · How we verify

NCT03210220

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Preoperative Pectoral Nerve Block for Intraoperative Opioid Sparing Effect and Postoperative Analgesia

Completed NA Results posted Last updated 18 November 2019

What this trial tests

NA trial testing Pecs II block in Breast Cancer in 40 participants. Completed in 1 August 2019.

Timeline

29 August 2017

Primary endpoint
30 December 2018

1 August 2019

Quick facts

Lead sponsor	Gachon University Gil Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	health services research
Enrollment	40
Start date	29 August 2017
Primary completion	30 December 2018
Estimated completion	1 August 2019
Sites	1 location across South Korea

Drugs / interventions tested

Pecs II block — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Gachon University Gil Medical Center

Who can join

Adults 20 to 65, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Intraoperative Remifentanil Consumption Primary · whole intraoperative period

Intraoperative remifentanil consumption during surgery(whole intraoperative period)

Group	Value	95% CI
Pecs Group	6.75	± 2.18
Control Group	10.12	± 3.68

Sponsor's own description

The purpose of this study is to determine whether pectoral nerves blocks（PECS） would reduces the opioid consumption during the surgery and postoperative pain after breast cancer surgery.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pectoral Nerve (PECs) block for postoperative analgesia-a systematic review and meta-analysis with trial sequential analysis.
Jin Z, Li R, Gan TJ, He Y, et al · · 2020 · cited 17× · PMID 32211121
Remifentanil-Sparing Effect of Pectoral Nerve Block Type II in Breast Surgery under Surgical Pleth Index-Guided Analgesia during Total Intravenous Anesthesia.
Choi JJ, Jo YY, Kim SH, Jung WS, et al · · 2019 · cited 17× · PMID 31394854 · DOI 10.3390/jcm8081181

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Gachon University Gil Medical Center trials

Trials by the same sponsor.

NCT07147114 — Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Pati · Phase 4 · recruiting
NCT05708157 — Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis · unknown
NCT06559202 — Inguinal and Axillary LN Size Distribution · completed
NCT04259918 — Effect of Alveolar Recruitment Maneuver on Postoperative Pain · NA · unknown
NCT04238351 — Transnasal Humidified Rapid Insufflation System for Intubation · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03210220 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gachon University Gil Medical Center
Last refreshed: 18 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03210220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing